Meta-analysis as a Diagnostic Tool for Predicting Disease Onset and/or Activity in Systemic Lupus Erythematosus
Systemic lupus erythematous (SLE) is a relatively rare disorder with prevalence rates between 5 and 50 per 100,000 population. This means performing any epidemiological analysis in a specific research center is difficult, due to the low number of cases within any one location. There is a need for biomarkers and diagnostic aids to monitor SLE disease activity and severity prior, during, and after treatment. Many specialist lupus clinics worldwide have published trials following in detail small numbers of patients that have been monitored for a disease biomarker, e.g., an autoantibody against a self-molecule in prospective a...
Source: Springer protocols feed by Immunology - February 7, 2014 Category: Allergy & Immunology Source Type: news
Treatment of Lupus Nephritis in the 21st CenturyTreatment of Lupus Nephritis in the 21st Century
Glomerulonephritis remains one of the most severe complications of systemic lupus erythematosus and is associated with significant morbidity and mortality. Immunotherapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 20, 2013 Category: Consumer Health News Tags: Allergy & Clinical Immunology Journal Article Source Type: news
Mixed Results for Combo Tx in Lupus Nephritis (CME/CE)
ATLANTA (MedPage Today) -- The addition of an immunomodulator to treatment for lupus nephritis did not significanly improve response rates at 6 or 12 months as compared with standard therapy alone, a randomized study showed. (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - November 12, 2013 Category: Journals (General) Source Type: news
Perils and Pitfalls of Long-term Effects of PPIsPerils and Pitfalls of Long-term Effects of PPIs
PPIs are associated with adverse effects such as thrombocytopenia, rhabdomyolysis, and acute interstitial nephritis. Expert Review of Clinical Pharmacology (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - September 27, 2013 Category: Gastroenterology Tags: Gastroenterology Journal Article Source Type: news
Lupus Nephritis Linked to Defective Immune Control Gene Lupus Nephritis Linked to Defective Immune Control Gene
Patients with SLE who had variations in the gene encoding the ABIN1 protein were at increased risk for kidney damage; the NF-kB pathway might provide new treatment targets in lupus nephritis. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 27, 2013 Category: Consumer Health News Tags: Rheumatology News Source Type: news
Gene Variations Tie Lupus to Nephritis (CME/CE)
(MedPage Today) -- Lupus nephritis was more common in individuals of European or African-American descent with particular gene variants, researchers found. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - August 24, 2013 Category: Primary Care Source Type: news
Kidney Disease in Lupus Is Not Always 'Lupus Nephritis'Kidney Disease in Lupus Is Not Always 'Lupus Nephritis'
Kidney disease in lupus is not always lupus nephritis. A kidney biopsy will help determine appropriate management. Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 23, 2013 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news
Nephritis May Raise Death Risk in Lupus (CME/CE)
(MedPage Today) -- The presence of renal involvement in patients with lupus was associated with a significantly increased mortality risk, a longitudinal Chinese study found. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - July 31, 2013 Category: Primary Care Source Type: news
Lupus Nephritis Tamed Without Steroids (CME/CE)
(MedPage Today) -- A combination regimen of rituximab (Rituxan) and mycophenolate mofetil (CellCept) successfully controlled lupus nephritis in 90% of patients without the need for oral corticosteroids, a prospective observational study found. (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - July 18, 2013 Category: Rheumatology Source Type: news
Ocrelizumab for Active Proliferative Lupus NephritisOcrelizumab for Active Proliferative Lupus Nephritis
Ocrelizumab does not significantly improve active proliferative lupus nephritis, but it does increase the rate of serious infections in some patients, according to the BELONG study. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 19, 2013 Category: Consumer Health News Tags: Rheumatology News Source Type: news
Update on the Treatment of Lupus NephritisUpdate on the Treatment of Lupus Nephritis
What are the latest treatment strategies for lupus nephritis? Are there any new therapies available to treat the disease? Current Opinion in Nephrology and Hypertension (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 28, 2013 Category: Consumer Health News Tags: Nephrology Journal Article Source Type: news
MMWR: synthetic pot suspected in cases of kidney failure
4.5 out of 5 stars
Acute Kidney Injury Associated with Synthetic Cannabinoid Use — Multiple States, 2012. MMWR 2013 Feb 15;62:93-98.
Full Text
About a year ago, TPR posted that several cases of acute renal failure following the use of synthetic cannabinoids had been reported in Wyoming. After this, the story seemed to drop off the map, and we were unable to obtain any additional information despite several calls to the Wyoming Department of Health.
The current issue of MMWR contains at important update. Following an alert issued after the 4 Wyoming cases were reported, 12 additional cases were detected in several st...
Source: The Poison Review - February 15, 2013 Category: Toxicology Authors: Leon Tags: Medical acute renal failure blueberry spice kidney injury synthetic cannabinoid Wyoming Source Type: news
FDA Updates Atazanavir Sulfate Capsule Labeling
“Recently [February 4, 2013] FDA approved changes to the Reyataz (atazanavir sulfate) capsule labeling to include the following changes.
“Section 5 Warnings and Precautions was revised to include cholelithiasis ...
“In section 6 Adverse Reactions: Postmarketing Experience, interstitial nephritis was added.
“In section 7 Drug Interactions: information regarding coadministration with boceprevir, carbamazepine, phenytoin, phenobarbital, lamotrigine and voriconazole was added.”
The updated labeling will be available at the FDA website.
More information is available:
FDA: Press rele...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - February 12, 2013 Category: Infectious Diseases Source Type: news
